To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

公司概况 - 公司专注于开发和销售针对周围神经损伤的外科解决方案 [1] - 公司在医疗保健领域运营，产品旨在修复和保护神经 [1] - 公司的主要竞争对手包括AtriCure Inc、Tactile Systems Technology Inc、BioLife Solutions Inc、AnaptysBio Inc以及Assembly Biosciences Inc [1] 财务表现分析 - 公司的投入资本回报率为2.07%，显著低于其8.72%的加权平均资本成本 [2][5] - 较低的ROIC表明公司未能产生超过其资本成本的回报，资本利用效率存在问题 [2][5] 同业比较 - 同业公司AtriCure Inc的ROIC为-6.47%，WACC为11.01%，ROIC与WACC比率为-0.59 [3] - 同业公司BioLife Solutions Inc的ROIC为-4.85%，WACC为12.57% [3] - 同业公司AnaptysBio Inc的ROIC为-28.56%，WACC为9.10% [3] - 同业公司Assembly Biosciences Inc的ROIC为-127.67%，WACC为6.45%，其ROIC与WACC比率低至-19.80，资本利用效率在同业中最为低下 [4][5]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to______________ Commission file number: 001-36046 Axogen, Inc. (Exact Name of Registrant as Specified in Its Charter) Minnesota (State or ot ...

AxoGen (AXGN) came out with quarterly earnings of $0.12 per share, beating the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.07 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +33.33%. A quarter ago, it was expected that this regenerative medicine company would post earnings of $0.06 per share when it actually produced earnings of $0.12, delivering a surprise of +100%.Over the last four quarters, ...

AxoGen (NasdaqCM:AXGN) Q3 2025 Earnings Call October 29, 2025 08:00 AM ET Company ParticipantsMichael Dale - CEO and DirectorLindsey Hartley - CFOCaitlin Roberts - Director of MedTech Equity ResearchJens Kemp - CMORick Ditto - VP of Global Health Economics, Reimbursement, and PolicyConference Call ParticipantsRoss Osborn - Director and Lead Research AnalystDavid Turkaly - Research AnalystMichael Sarcone - AnalystAnthony Petrone - Managing Director, Senior Medical Devices, Diagnostics, and Therapeutics Equit ...

AxoGen (NasdaqCM:AXGN) Q3 2025 Earnings Call October 29, 2025 08:00 AM ET Company ParticipantsMichael Dale - CEO and DirectorLindsey Hartley - CFOCaitlin Roberts - Director of MedTech Equity ResearchJens Kemp - CMORick Ditto - VP of Global Health Economics, Reimbursement, and PolicyConference Call ParticipantsRoss Osborn - Director and Lead Research AnalystDavid Turkaly - Research AnalystMichael Sarcone - AnalystAnthony Petrone - Managing Director, Senior Medical Devices, Diagnostics, and Therapeutics Equit ...

AxoGen (NasdaqCM:AXGN) Q3 2025 Earnings Call October 29, 2025 08:00 AM ET Speaker5Good morning. Joining me on today's call is Michael Dale, AxoGen's Chief Executive Officer and Director, and Lindsey Hartley, Chief Financial Officer. Michael will discuss third quarter 2025 financial results and corporate highlights. Lindsey will then provide details on financial performance, guidance, and overall outlook for the year. This will be followed by a question and answer session. Today's call and presentation is be ...

Q3 2025 Financial Results October 29, 2025 1 Disclaimer Forward-looking Statements About Non-GAAP Financial Measures To supplement our condensed consolidated financial statements, we use the non-GAAP financial measures of EBITDA, which measures earnings before interest, income taxes, depreciation and amortization, EBITDA margin, Adjusted EBITDA, which further excludes non-cash stock compensation expense, and Adjusted EBITDA margin. We also use the non-GAAP financial measures of Adjusted Net Income (Loss) an ...

Exhibit 99.1 Axogen, Inc. Reports Third Quarter 2025 Financial Results Raises Full Year Revenue Guidance to at Least 19% Growth or $222.8 million ALACHUA and TAMPA, FL – October 29, 2025 – Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today reported financial results and business highlights for the third quarter ended September 30, 2025. Third Quarter Financial Results • Third quarter 2025 revenue grow ...

Raises Full Year Revenue Guidance to at Least 19% Growth or $222.8 millionALACHUA, Fla. and TAMPA, Fla., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today reported financial results and business highlights for the third quarter ended September 30, 2025. Third Quarter Financial Results Third quarter revenue was $60.1 million, a 23.5% increase compared to the third qua ...